Alliance Pharma PLC Pre-Close Trading Update (7833L)
July 09 2014 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 7833L
Alliance Pharma PLC
09 July 2014
For immediate release 9 July 2014
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Pre-Close Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, announces its pre-close trading update ahead of the
announcement of its interim results for the six months ended 30
June 2014.
Trading for the first half of the year has been in line with
management's expectations, with total turnover including share of
joint ventures of approximately GBP22.5 million (2013: GBP22.8
million). Group turnover excluding share of joint ventures was
approximately GBP21.4 million (2013: GBP22.8 million).*
Hydromol(TM) continues to grow well, with sales of GBP3.0
million in the period, 15% higher than in the same period the
previous year.
Sales of Ashton & Parsons Infants' Powder(TM) reached GBP0.7
million in the period, compared with just GBP0.1 million in the
same period the previous year, when production capacity was
severely constraining our ability to meet demand.
Sales of Nu-Seals(TM) continue to hold up well, with GBP1.4
million in the half year (2013: GBP1.6 million).
The recent acquisitions of Lypsyl(TM) in the UK and Ireland and
Irenat(TM) in Germany are performing broadly in line with
expectations, with Lypsyl delivering GBP0.5 million sales and
Irenat GBP0.4 million sales in the period.
We continue to expect trading performance in 2014 to be in line
with our plans, before the positive impact of any further
acquisitions. Around GBP22 million of our acquisition bank facility
remains undrawn and available to fund opportunities as they
arise.
The Company's interim results for the six months ended 30 June
2014 are scheduled to be released on 10 September 2014.
*In 2014 Alliance is adopting International Financial Reporting
Standard 11 and as a consequence will include joint ventures using
equity accounting rather than proportional consolidation. Group
turnover will no longer include share of joint venture
turnover.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Fiona Henson /
Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: David Poutney
Notes to editors:
Alliance, founded in 1998, is an AIM listed speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to
established niche products and owns or licenses the rights to more
than 60 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSSAFMAFLSESW
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024